Ann-Cathrine Dalgård Dunvald

12PUBLICATIONS
38CO-AUTHORS
PharmacogenomicsMolecular targetsMultimorbidityCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 12, 2026
Use of STOPPFrail Medications Following Receipt of the Danish Terminal Grant: A Nationwide Descriptive Study.

|Aug 19, 2024
Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.

Ditte B Iversen, Ann-Cathrine Dalgård Dunvald, Martin Thomsen Ernst

|Aug 08, 2024
The Effectiveness of Collaborative Care Interventions for the Management of Patients With Multimorbidity: Protocol for a Systematic Review, Meta-Analysis, and Meta-Regression Analysis.

Anne-Maj Knudsen, Ann-Cathrine Dalgård Dunvald, Stine Hangaard

|Oct 13, 2023
Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.

Ann-Cathrine Dalgård Dunvald, Kasper Søltoft, Ekta Sheetal

|May 26, 2023
Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes.

Ditte B Iversen, Ann-Cathrine Dalgård Dunvald, Daniel M Jespersen

|Apr 06, 2023
Dicloxacillin-warfarin drug-drug interaction-A register-based study and in vitro investigations in 3D spheroid primary human hepatocytes.

Erkka Järvinen, Ann-Cathrine Dalgård Dunvald, Martin Thomsen Ernst

Pageof 2

Frequent Collaborators

9 joint publications

Tore Bjerregaard Stage

5 joint publications

Erkka Järvinen

4 joint publications

Ditte Bork Iversen

4 joint publications

Anton Pottegård